Active Studies

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
patients with connective tissue disease-associated pulmonary arterial hypertension to
determine the recommended dose range and evaluate the change from baseline in 6-minute walk
distance (6MWD) following 24 weeks of study participation.

The purpose of this study is to determine whether the researchers can help people change the
amount of time they spend in sitting activities and whether this change might improve health
outcomes.

The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist
given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial
fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in
the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors
(such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a
comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K
antagonist, such as warfarin, with or without aspirin.

This research trial studies Yttrium Y 90 resin microspheres in collecting data from patients
with liver cancer not capable of being removed by surgery (unresectable) for the
radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres) in non-resectable
(RESIN) liver tumor registry. The information generated will help doctors better understand
treatment patterns involving Y90 therapy, gain additional insights in the long-term outcomes
for patients, as well as guide future research for using Y90 therapy, especially for those
conditions where data is currently very limited or lacking.

The purpose of this research is to determine if an investigational new drug solution called
Prismocitrate 18 lengthens extracorporeal circuit life in acute kidney injury (AKI) patients
treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT
treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who
receive CRRT treatment with no anticoagulation.

Pages